Sydney E. Salmon, MD

Affiliations: 
Medicine/Oncology University of Arizona College of Medicine 
Area:
Chemotherapy, clinical trials
Website:
https://clincancerres.aacrjournals.org/content/6/1/316
Google:
"Sydney Salmon"
Bio:

Dr. Salmon led the UA Cancer Center from its founding in 1976 until 1998, just before his death from pancreatic cancer. He steered cancer research at the UA from 1972, including overseeing a planning grant from the National Cancer Institute (NCI), the formation of the Southwest Oncology Group that allowed the UA to participate in larger clinical trials, and two program project grants from NCI, all of which led to the Cancer Center’s first federal support grant in 1978.

Dr. Salmon’s areas of research interest were in multiple myeloma, breast cancer and tissue culture studies of human cancers. Under Dr. Salmon's leadership, the center grew rapidly and became a major resource for the treatment of cancer in the Southwest. The center's first building, the Leon F. Levy Building, was dedicated in 1986 providing clinical, administrative and research facilities.

In 1989 the Arizona Board of Regents named Dr. Salmon as a Regents Professor of Medicine. The following year, the NCI designated the UA Cancer Center as a "comprehensive cancer center," which the NCI determines to have outstanding basic and clinical cancer research and patient care. In 1991, Dr. Salmon was named by President George H. W. Bush to the NCI's senior advisory board, the National Cancer Advisory Board, for a five-year term.

The center's second building, the Sydney E. Salmon, MD, Building, was named by the Arizona Board of Regents to honor Salmon and was dedicated in January 1998.

During the course of his career, Salmon served as president of ASCO (1984-85) and the American Association of Cancer Institutes (1989-1990).

He held eight patents, several of which have had major impact on biology and medicine, and he served as an advisor to both government and the pharmaceutical industry. He was founding scientist of the Selectide Corp. in Oro Valley, now Sanofi-Aventis. Dr. Salmon also is the recipient of many awards for his achievements in cancer research. He is the author of nearly 400 scholarly papers, and he edited 12 books in fields related to cancer research or cancer treatment.
(Show less)

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Barlogie B, Kyle RA, Anderson KC, et al. (2006) Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 929-36
Flanigan RC, Salmon SE, Blumenstein BA, et al. (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. The New England Journal of Medicine. 345: 1655-9
Taylor CW, Dorr RT, Fanta P, et al. (2001) A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 47: 83-8
Monk BJ, Alberts DS, Burger RA, et al. (1998) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers Gynecologic Oncology. 71: 308-312
Miller TP, Chase EM, Dorr R, et al. (1998) A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-Cancer Drugs. 9: 135-40
Salmon SE, Crowley JJ, Balcerzak SP, et al. (1998) Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 890-6
Alberts DS, Fanta PT, Running KL, et al. (1997) In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemotherapy and Pharmacology. 39: 493-497
Taylor CW, Dalton WS, Mosley K, et al. (1997) Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Research and Treatment. 42: 7-14
Parza NZ, Taetle R, Nelson M, et al. (1997) Chromosome instability in 75 untreated ovarian cancer patients Cancer Genetics and Cytogenetics. 98: 171
Taetle R, Aickin M, Thompson F, et al. (1997) Clinical cytogenetic correlations in solid tumors Cancer Genetics and Cytogenetics. 98: 151
See more...